Compare Lithium Americas Corp (LAC) vs 10X Genomics Inc (TXG) Price & Performance

Lithium Americas (LAC) trades at $2.90, down 1.69% on the day, with a bearish technical signal but bullish oscillators. The company reported a net loss of $122.09 million for 2025, with negative ROE and ROA, though it beat EPS estimates in two of the last three quarters. Recent news highlights progress at the Thacker Pass project and potential government support for rare earth minerals, but oversupply concerns weigh on the sector.

The outlook is mixed: analyst consensus leans slightly bullish with no sell ratings, but high cash burn and capital needs pose significant risks. Investment opportunity hinges on successful project execution and lithium demand recovery, while key risks include funding dilution, operational delays, and commodity price volatility.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.